• Tazobactam packaged and labeled.

click on thumbnail to zoom
SKU: T001

  Click 'Bulk Order' for 10 or more
Price: make selection(s)

Tazobactam is a penicillanic acid sulfone derivative and beta-lactamase inhibitor with antibacterial activity. Tazobactam was discovered by Dr. R.G. Micetech at the University of Alberta in 1982. Tazobactam contains a beta-lactam ring and irreversibly binds to beta-lactamase at or near its active site. This protects other beta-lactam antibiotics from beta-lactamase catalysis. This drug is used in conjunction with beta-lactamase susceptible penicillins to treat infections caused by beta-lactamase producing organisms.

Tazobactam alone showed an MIC of ≤ 8 mg/liter (range 2 to 32 mg/liter) against several Acinetobacter baumannii strains. Tazobactam in combination with piperacillin, successfully restored the activity of piperacillin against β-lactamase-producing bacteria. Tazobactam exhibited inhibitory activity and protected piperacillin against Richmond and Sykes types II, III, IV and V β-lactamases, staphylococcal penicillinase and extended-spectrum β-lactamases. Tazobactam showed species-specific activity against class I chromosomally-mediated enzymes.

TOKU-E offers two forms of tazobactam: tazobactam (T001) and tazobactam sodium (T031). Tazobactam is slightly soluble in aqueous solution (9.59 mg/mL). Tazobactam sodium is freely soluble in aqueous solution.

    CAS Number


    Molecular Formula


    Molecular Weight


    Mechanism of Action

    Tazobactam contains a beta-lactam ring that binds strongly to beta-lactamase at or near its activation site, thereby permanently inhibiting enzymatic activity.  This action protects other beta-lactam antibiotics (penicillins, cephalosporins, etc.) from beta-lactamase catalysis, thereby enhancing their antibacterial activity.

    Storage Conditions


    Tariff Code



    Tazobactam exhibits little useful antimicrobial activity, although weak activity against Acinetobacter spp. and Borrelia burgdorferi has been reported.

    Tazobactam inhibits a wide range of β-lactamases, including the group 2 penicillinases from Staph. aureus, the TEM-1 and SHV-1 β-lactamases, many extended-spectrum enzymes, and the common group 2e cephalosporinases of B. fragilis. Against the group 1 cephalosporinases, activity is strongly influenced by the amount of enzyme produced. The inhibitor-resistant group 2br β-lactamases are poorly inhibited and group 3 metallo-β-lactamases are not inhibited at clinically useful levels. It is a poor inducer of β-lactamases of Gram-positive and Gram-negative organisms.


    Microbiology Applications

    Tazobactam is often combined with the extended-spectrum β-lactam antibiotic piperacillin in the drug zosyn or Tazocin (piperacillin/tazobactam), used in infections due Pseudomonas aeruginosa. Tazobactam broadens the spectrum of piperacillin by making it effective against organisms that express β-lactamase and would normally degrade piperacillin.





    White or almost white crystalline powder



    Water Content (Karl Fischer)

    Not more than 4.0%


    2.0 - 2.5


    (On Dried Basis): Not less than 94.0%

    Residue On Ignition

    Not more than 0.1%

    Heavy Metals

    Not more than 20 ppm



    Craig, W.A., and Andes, D.R. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob. Agents Chemother. 57(4),1577-1582 (2013).

    Wishart, David. "Tazobactam." DrugBank. The Metabolomics Innovation Center, 13 June 2005. Web. 23 Aug. 2012.

    Drawz, S.M., and Bonomo, R.A. Three decades of β-lactamase inhibitors. Clin.Microbiol.Rev. 23(1), 160-201 (2010).

    Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014 Jan;74(1):31-51. PMID: 24352909

    Frase H, Smith CA, Toth M, et al. Identification of products of inhibition of GES-2 beta-lactamase by tazobactam by x-ray crystallography and spectrometry. J Biol Chem. 2011 Apr 22;286(16):14396-409. PMID: 21345789.

    Jones, R.N., Pfaller, M.A., Fuchs, P.C., et al. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn. Microbiol. Infect. Dis. 12(6), 489-494 (1989).

    Bryson, H.M. and Brogden, R.N. 1994. Drugs. 47: 506-535. PMID: 7514977

Other Items In This Category

Related Products